Georgia Patent of the Month – September 2022
Many people suffer from bacterial infections and aggressive cancers that are not effectively treated with medications currently available. Progressive Multifocal Leukoencephalopathy (PML) is a fatal brain infection caused by the JC polyomavirus (JCV) and typically targets immunocompromised individuals. Chronic Myeloid Leukemia (CML) is a type of cancer that targets the bone marrow. The leading treatments for both of these diseases provide a great survival rate, but have low tolerability, leading to relapse of the disease and also may cause severe side effects.
Imatinib, a common growth blocker known as a tyrosine kinase inhibitor (TKI), can effectively increase the survival rate of patients suffering from CML, but can cause side effects such as gastrointestinal issues, hypertension, or pleural effusions. Imatinib can also treat PML, but the safe concentration of this medication does not provide an efficacious dose to treat the infection.
Inhibikase Therapeutics, Inc. is focused on providing patients with safe, effective, and potent treatments for bacterial infections and cancer while reducing negative side effects. They developed an oral, brain-penetrant treatment that blocks entry of the JCV in the cell, preventing damage to neural tissue in individuals suffering from PML. They combined a variety of compounds along with Imatinib to provide a safer treatment for CML that removes gastrointestinal side effects, improving patient tolerability and long-term medication use. With these medical advancements, Inhibikase Therapeutics, Inc. decreases the possibility of disease relapse for all patients, significantly improving their quality of life.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.